#Sweden #Gothenburg #PH-ILD #Cereno Scientific #CS014

Cereno Scientific Expands Focus of CS014 Development

Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotechnology firm, has announced a shift in the developmental objectives of its leading treatment candidate, CS014. Originally aimed at treating idiopathic pulmonary fibrosis (IPF), the focus will now expand to include pulmonary hypertension associated with interstitial lung disease (PH-ILD). This strategic change intends to better align the clinical development program with the pressing needs of patients suffering from this devastating condition.

The Significance of PH-ILD

Pulmonary hypertension itself is a severe complication that frequently arises in patients diagnosed with various forms of interstitial lung disease, including IPF. This progression not only exacerbates the patient's overall health but also leads to significantly worse outcomes, including reduced exercise capacity and increased mortality rates.

CEO Sten R. Sörensen highlighted that this broadened focus on PH-ILD represents a scientifically driven evolution in the development of CS014. “It allows us to target a condition with very limited treatment options while also enhancing our clinical and strategic positioning,” he stated. By investigating CS014 in this population, the company anticipates a greater chance of providing a meaningful therapeutic solution for patients who currently face an uphill battle with very few available treatments.

Underlying Mechanisms Targeted by CS014

CS014 functions as a novel HDAC inhibitor designed to address the complex mechanisms underlying both fibrotic lung disease and pulmonary vascular issues. The shared pathophysiology between these diseases—encompassing processes like vascular remodeling, inflammation, and fibrosis—provides a compelling rationale for focusing clinical assessments on PH-ILD. According to Chief Medical Officer Rahul Agrawal, this paradigm shift enables the design of Phase II clinical trials that more accurately mirror real-world disease biology, enhancing the potential for success in meeting clinical endpoints.

Clinical Development Progress

Cereno Scientific has already completed a Phase I study for CS014, which established a favorable safety profile and showed promising efficacy signals. With the recent decision to broaden the indication, the company is gearing up to initiate a Phase II study exclusively targeting PH-ILD in the first quarter of 2027. This study aims to address the unmet medical needs of patients who experience both fibrotic lung diseases and pulmonary hypertension.

Future Outlook

With a clear path toward clinical testing and potential market entry, CS014 stands as a beacon of hope for the community grappling with severe cardiopulmonary diseases. By shifting its developmental strategy to encompass a more relevant and challenging patient population, Cereno Scientific exemplifies its commitment to ameliorating the health and lives of patients suffering from complex conditions. As the company continues to advance its pipeline, it reaffirms its position as a leader in the development of next-generation treatments for patients with significant unmet medical needs.

For additional details on the promising developments surrounding CS014 and Cereno Scientific's innovative approaches to treatment, visit their official website or connect with investor relations directly.

• ---

For inquiries, please reach out to Tove Bergenholt at Cereno Scientific.